The outlook for equity markets looks "decent" going into 2025, according to Barclays, as central banks cut interest rates and the global economy remains resilient. "Given limited valuation uplift for frothy parts of the market, global equities may struggle to deliver outsized risk-adjusted returns again in 2025. But they still screen favorably vs. bonds, cash and credit," the investment bank's analysts wrote in a Nov. 18 research note.
"We think now is a compelling entry point in AstraZeneca, as 2025 looks set to be a year of ground- breaking catalysts," the analysts explained. These catalysts include an $80-billion revenue target for 2030 which the company announced in May — around $10 billion higher than expected at the time. Shares in AstraZeneca are listed on the London and Stockholm Stock Exchanges and trade as an ADR in the U.S. under the ticker AZN .
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
منبع: Investingcom - 🏆 450. / 53 ادامه مطلب »
منبع: ForbesTech - 🏆 318. / 59 ادامه مطلب »